Anticoagulation in Renal Dysfunction

Introduction to Anticoagulant Options

The European Society of Cardiology recommends apixaban and rivaroxaban as preferred anticoagulants for patients with renal dysfunction, with specific dose adjustments based on the degree of renal impairment 1, 2
For patients with mild to moderate renal impairment (CrCl 30-80 mL/min), all NOACs can be used with appropriate dose adjustments, with apixaban and rivaroxaban being preferred options 1, 2

For mild to moderate renal impairment (CrCl 30-80 mL/min), the recommended doses are: apixaban 5 mg twice daily (reduce to 2.5 mg twice daily if two of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL), rivaroxaban 15-20 mg once daily (15 mg for CrCl 30-49 mL/min), edoxaban 30-60 mg once daily (30 mg for CrCl 30-49 mL/min), dabigatran 150 mg twice daily (outside US, 110 mg twice daily may be used in elderly or high bleeding risk), and VKAs (e.g., warfarin) with target INR 2-3 and good time in therapeutic range (TTR >65-70%) 1, 2
For severe renal impairment (CrCl 15-29 mL/min), rivaroxaban (15 mg once daily), apixaban (2.5 mg twice daily), and edoxaban (30 mg once daily) are approved in Europe, with apixaban being preferable due to lowest renal clearance (27%) 1, 2
For end-stage renal disease (CrCl <15 mL/min or dialysis), limited data exists, but well-managed VKAs (TTR >65-70%) may be considered, and apixaban 5 mg twice daily is approved in the US for chronic, stable dialysis patients 1, 2

Low molecular weight heparins (LMWH) require dose reduction for CrCl <30 mL/min, with enoxaparin requiring dose adjustment if CrCl <30 mL/min 3
Fondaparinux is contraindicated if CrCl <30 mL/min, but may be considered due to lower bleeding risk compared to enoxaparin 3, 4
Bivalirudin should be reduced to 1.0 mg/kg/h if CrCl <30 mL/min, and to 0.25 mg/kg/h for hemodialysis patients 3, 4

Tirofiban requires 50% dose reduction if CrCl <30 mL/min 3, 4
Eptifibatide should be reduced to 1 mg/kg/min if CrCl <50 mL/min, and is contraindicated if CrCl <30 mL/min 3, 4
Abciximab requires careful evaluation of bleeding risk, but no specific dose adjustment is needed 3, 4

Regular assessment of renal function is recommended, especially in NOAC users, with adjustment of doses based on current renal function 1, 2
For VKAs, maintaining TTR >65-70% is recommended 2
Combining anticoagulants with antiplatelets, NSAIDs, or SSRIs should be avoided when possible to reduce bleeding risk 5
The American Heart Association recommends considering drug-drug interactions that may increase bleeding risk 5

The American Heart Association recommends reducing rivaroxaban to 15 mg once daily for atrial fibrillation patients with mild to moderate CKD (CrCl 30-50 mL/min) 6, 7
The European Society of Cardiology recommends rivaroxaban 15 mg once daily for severe CKD (CrCl 15-29 mL/min) patients, with close monitoring for signs of bleeding 8
Warfarin (INR 2.0-3.0) is the recommended anticoagulant for end-stage renal disease (ESRD) and dialysis patients, as rivaroxaban and dabigatran are not recommended due to lack of clinical trial evidence in this population 6

Apixaban may be preferable in severe CKD due to its lowest renal clearance (27%) and demonstrated relative safety improvement with declining renal function 8
Edoxaban has 50% renal clearance and requires dose reduction to 30 mg for CrCl 30-50 mL/min 8
Dabigatran should be avoided in significant CKD due to its 80% renal clearance 8

Renal function should be assessed at least yearly in all NOAC patients, and more frequently in those with CrCl <60 mL/min, with the frequency determined by dividing CrCl by 10 to determine monitoring frequency in months 8
Renal function should be reassessed during acute illness, such as infections or heart failure, as these can transiently worsen renal function 8

The European Society of Cardiology recommends that apixaban can be initiated in patients with creatinine clearance (CrCl) ≥15 mL/min, but dose reduction to 2.5 mg twice daily is required for CrCl 15-29 mL/min or when two of three criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 9

For patients with CrCl ≥50 mL/min, the standard dose is 5 mg twice daily, with no dose adjustment required based on renal function alone 9
For patients with CrCl 30-49 mL/min, the standard dose is 5 mg twice daily, but reduction to 2.5 mg twice daily is recommended if two of the following criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 9, 10
For patients with CrCl 15-29 mL/min, a reduced dose of 2.5 mg twice daily is recommended 9
For patients with CrCl <15 mL/min or on dialysis, the dosing recommendations vary by region, with 5 mg twice daily approved in the United States for chronic, stable dialysis-dependent patients, but not routinely recommended in Europe due to lack of hard endpoint data 9

The American Diabetes Association recommends assessing renal function at least annually in all apixaban patients, with more frequent monitoring for patients with CrCl <60 mL/min 11